{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:14:05Z","timestamp":1740147245448,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Breast cancer is the most common cancer in women. Progression-free survival for hormone receptor-positive\/human epidermal growth factor receptor-2-negative metastatic breast cancer treated with endocrine therapy in combination with cyclin4\/6-dependent kinase is approximately 25 months. This case represents metastatic breast cancer treated with endocrine therapy, leading to long-term survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 40-year-old Syrian woman diagnosed with hormone receptor-negative breast cancer was treated surgically with adjuvant chemotherapy and radiotherapy. She developed local and nodal recurrences that were hormone receptor-positive, followed by a recurrence of malignant pleural effusion. She was initially treated with chemotherapy and then placed on endocrine therapy with a complete response from 2014 until now. The patient also suffered from adverse events of medications, such as heart failure and osteoporosis, which were treated appropriately.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This case demonstrates a long-lasting complete response to metastatic breast cancer with malignant pleural effusion. This shows the validity of endocrine therapy in recurrent hormone receptor-positive breast cancer, especially in countries that cannot afford targeted therapies or genetic tests. It also highlights the necessity for a better understanding of the prognostic and predictive factors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-024-04734-6","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:02:50Z","timestamp":1725408170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complete response and long-term survival to endocrine monotherapy in a patient with metastatic breast cancer in a low-income country: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Raghad","family":"Sada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nouralhuda","family":"Karim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghina","family":"Rohaibani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mousa","family":"Alali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5418-3186","authenticated-orcid":false,"given":"Maher","family":"Saifo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"issue":"3","key":"4734_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4734_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4103\/2231-4040.72251","volume":"1","author":"GN Sharma","year":"2010","unstructured":"Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res. 2010;1(2):109.","journal-title":"J Adv Pharm Technol Res."},{"issue":"7","key":"4734_CR3","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541\u20137.","journal-title":"Ann Oncol"},{"key":"4734_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/CMAR.S409918","volume":"15","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhou T, Zhao S, Li N, Sun S, Li M. A novel clinical prognostic model for breast cancer patients with malignant pleural effusion: avoiding chemotherapy in low-risk groups? Cancer Manage Res. 2023;15:409\u201322.","journal-title":"Cancer Manage Res"},{"issue":"3","key":"4734_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/jso.2930580307","volume":"58","author":"JP Apffelstaedt","year":"1995","unstructured":"Apffelstaedt JP, van Zyl JA, Muller AGS. Breast cancer complicated by pleural effusion: patient characteristics and results of surgical management. J Surg Oncol. 1995;58(3):173\u20135. https:\/\/doi.org\/10.1002\/jso.2930580307.","journal-title":"J Surg Oncol"},{"issue":"Suppl 2","key":"4734_CR6","doi-asserted-by":"publisher","first-page":"ii32","DOI":"10.1136\/thx.2010.136994","volume":"65","author":"ME Roberts","year":"2010","unstructured":"Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii32.","journal-title":"Thorax"},{"issue":"6","key":"4734_CR7","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","volume":"21","author":"WJ Gradishar","year":"2023","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast Cancer, Version 4.2023 featured updates to the NCCN guidelines. JNCCN J Nat Comprehen Cancer Netw. 2023;21(6):594\u2013608.","journal-title":"JNCCN J Nat Comprehen Cancer Netw."},{"issue":"3","key":"4734_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10549-010-1091-9","volume":"125","author":"JM Dixon","year":"2011","unstructured":"Dixon JM, Renshaw L, Langridge C, Young OE, McHugh M, Williams L, et al. Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability. Breast Cancer Res Treat. 2011;125(3):741\u20139. https:\/\/doi.org\/10.1007\/s10549-010-1091-9.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"4734_CR9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(18)30047-0","volume":"6","author":"TD Rachner","year":"2018","unstructured":"Rachner TD, Coleman R, Hadji P, Hofbauer LC. Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol. 2018;6(11):901\u201310. https:\/\/doi.org\/10.1016\/S2213-8587(18)30047-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"4734_CR10","first-page":"E20396","volume":"99","author":"R Maltoni","year":"2020","unstructured":"Maltoni R, Palleschi M, Gallerani G, Bravaccini S, Cecconetto L, Melegari E, et al. Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer: a case report. Medicine (United States). 2020;99(24):E20396.","journal-title":"Medicine (United States)"},{"key":"4734_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrc.2014.11.002","volume":"3","author":"G Pahouja","year":"2015","unstructured":"Pahouja G, Wesolowski R, Reinbolt R, Tozbikian G, Berger M, Mangini N, et al. Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicin. Cancer Treat Commun. 2015;3:28\u201332.","journal-title":"Cancer Treat Commun."},{"issue":"6","key":"4734_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0953-6205(00)00121-7","volume":"11","author":"G Freyer","year":"2000","unstructured":"Freyer G, Ligneau B, Trillet-Lenoir V. Palliative hormone therapy, low-dose chemotherapy, and bisphosphonate in breast cancer patients with bone marrow involvement and pancytopenia: report of a pilot experience. Eur J Intern Med. 2000;11(6):329\u201333. https:\/\/doi.org\/10.1016\/S0953-6205(00)00121-7.","journal-title":"Eur J Intern Med"},{"issue":"12","key":"4734_CR13","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/dc.23607","volume":"44","author":"IM Francis","year":"2016","unstructured":"Francis IM, Alath P, George SS, Jaragh M, Al Jassar A, Kapila K. Metastatic breast carcinoma in pleural fluid: correlation of receptor and HER2 status with the primary carcinoma\u2014a pilot study. Diagn Cytopathol. 2016;44(12):980\u20136. https:\/\/doi.org\/10.1002\/dc.23607.","journal-title":"Diagn Cytopathol"},{"key":"4734_CR14","doi-asserted-by":"crossref","unstructured":"Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of Anthracyclines. Vol. 7, Frontiers in Cardiovascular Medicine. Frontiers Media S.A.; 2020.","DOI":"10.3389\/fcvm.2020.00026"},{"key":"4734_CR15","doi-asserted-by":"publisher","first-page":"e0241775","DOI":"10.1371\/journal.pone.0241775","volume":"15","author":"J Crespo","year":"2020","unstructured":"Crespo J, Sun H, Wu J, Ding QQ, Tang G, Robinson MK, et al. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO\/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy. PLoS ONE. 2020;15:e0241775.","journal-title":"PLoS ONE"},{"issue":"1","key":"4734_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13000-021-01187-z","volume":"17","author":"H Kong","year":"2022","unstructured":"Kong H, Bai Q, Li A, Zhou X, Yang W. Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO\/CAP guideline. Diagn Pathol. 2022;17(1):5.","journal-title":"Diagn Pathol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04734-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-024-04734-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04734-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:08:39Z","timestamp":1725408519000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-024-04734-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4734"],"URL":"https:\/\/doi.org\/10.1186\/s13256-024-04734-6","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"30 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed involving human participants were under the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by the institutional review board of Damascus University, and the committee\u2019s reference number was MD-160124-173 on 16 January 2024.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"405"}}